Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
Research and Development : R&D expenses decreased to $86.8 million in 2023 from $155.0 million in 2022, reflecting strategic focus and operational efficiencies. General and Administrative Expenses : G&A expenses reduced to $42.1 million in 2023 from $59.9 million in 2022, due to decreased headcount and professional fees. Net Loss : Reported a net loss of $123.3 million for the year ended December 31, 2023, compared to a net loss of $214.0 million for the previous year. Collaboration Revenue : Recognized $2.4 million in collaboration revenue in 2023 related to the Option and License Agreement with UCB. Stock Performance : As of December 31, 2023, Praxis had 8.8 million shares of common stock outstanding. Warning! GuruFocus has detected 3 Warning Sign with PRAX. On March 5, 2024, Praxis Precision Medicines Inc ( NASDAQ:PRAX ), a clinical-stage biopharmaceutical company focused on CNS disorders, released its 8-K filing , providing a corporate update and reporting financial r
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $117.00 price target on the stock.MarketBeat
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.MarketBeat
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
PRAX
Earnings
- 3/5/24 - Beat
PRAX
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 3/29/24 - Form 8-K
- PRAX's page on the SEC website